Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 162 for your search:
Drug:
melphalan
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma
Phase:
Phase IV, Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
GPOH-NB2004
, EU-20661, NCT00410631
2.
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
TaCyDexVMP7
, NCT00652041
3.
Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-00055-18
, NCT00415103
4.
Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
5.
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
UARK 2003-26
, NCT00090493
6.
Thalidomide/Dexamethasone Vs MP for Induction Therapy and Thalidomide/Intron A Vs Intron A for Maintenance Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
19 and over
Sponsor:
Other
Protocol IDs:
01-002-0601
, NCT00205751
7.
Stem Cell Transplantation for Hematological Malignancies
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
35 and under
Sponsor:
Other
Protocol IDs:
0005M52481
, MT2000-12, 2000LS040, NCT00176839
8.
Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
UHW-AML16
, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
9.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
10.
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2006-0374
, NCT00539500
11.
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-Dexamethasone (Vel/Dex) Followed by HDT With ASCT
Phase:
Phase III, Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
R08096M
, VEL-1-08-DK-002, 26866138MMY2063, NCT00861250
12.
Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
CKTO-2000-06
, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
13.
Phase III Randomized Study of Standard Induction Chemotherapy Comprising Vincristine, Dactinomycin, Ifosfamide, and Etoposide Followed By Consolidation Chemotherapy Comprising Vincristine, Dactinomycin, and Ifosfamide Versus High-Dose Busulfan and Melphalan Followed By Autologous Peripheral Blood Stem Cell Support With or Without Radiotherapy and/or Surgery in Patients With Tumor of the Ewing's Family
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 50
Sponsor:
NCI, Other
Protocol IDs:
EURO-EWING-INTERGROUP-EE99
, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, NCT00020566, AEWS0331
14.
Phase III Randomized Study of Induction Chemotherapy With or Without Filgrastim (G-CSF) Followed By Surgery, Myeloablative Therapy, and Radiotherapy With Isotretinoin With or Without Monoclonal Antibody Ch14.18 in Patients With High-Risk Neuroblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
1 to 20 at diagnosis
Sponsor:
Other
Protocol IDs:
SIOP-EUROPE-HR-NBL-1
, ESIOP, EU-20148, NCT00030719
15.
Phase III Randomized Study of Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
CALGB-100104
, ECOG-CALGB-100104, NCT00114101
16.
Phase III Randomized Study of Induction Therapy Comprising Two Different Doses of High-Dose Melphalan and Amifostine Followed by Single or Double Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Maintenance Therapy Comprising Clarithromycin, Thalidomide, and Dexamethasone in Patients With Stage II or III Multiple Myeloma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-2004.00
, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
17.
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
19 to 70
Sponsor:
Other
Protocol IDs:
03/99
, NCT00205764
18.
Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus R-CHOP/R-DHAP in Patients With Untreated Mantle Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
MCL2004-2
, NCT00209222
19.
Phase III Randomized Study of Percutaneous Isolated Hepatic Arterial Perfusion With Melphalan With Subsequent Venous Hemofiltration Versus Best Alternative Standard Treatment in Patients With Unresectable Liver Metastases Secondary to Ocular or Cutaneous Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0088
, NCI-P6701, NCT00324727
20.
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
NHLBI
Protocol IDs:
384
, BMT CTN 0401, U01 HL069294-05, NCT00329030
21.
Efficacy of Bortezomib Consolidation After High-Dose Melphalan With Stem Cell Support in Myeloma Patients
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
NMSG 15/05
, EudraCT No: 2005-002756-18, NCT00417911
22.
Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma
Phase:
Phase III
Type:
Diagnostic, Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
EURONET-PHL-C1
, EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10
23.
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
66 and over
Sponsor:
Other
Protocol IDs:
2005-001111-21
, NCT00443235
24.
GEM05 for Patients With Multiple Myeloma Under 65 Years
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
Other
Protocol IDs:
2005-001110-41
, NCT00461747
25.
Phase III Randomized Study of Low-Dose Melphalan and Dexamethasone Versus High-Dose Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Primary Systemic Amyloidosis
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0482
, MAYO-IRB-1691-05, MC0482, NCT00477971
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
